Cancer Family
Malignant Breast Neoplasm
CI-CAN-00000227Explore in graph →
Top-level2,627 active trials43 approved drugs310 evidence items
- NCIt
- C9335
- ICD-10
- C50
- DOID
- 1612
- Other
- 2 more codes
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000227Explore in graph →
Clinical trials
12,360 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (1,368)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT05559164 | Statins for Reduction of Cardiac Toxicity in Patients Receiving HER2 Targeted | recruiting | Phase 2 | 60 | Rutgers, The State University of New JerseyOTHER | 1 | Nov 14, 2025 | clinicaltrials |
| NCT04553770 | Trastuzumab Deruxtecan Alone or in Combination With Anastrozole for the Treatment of Early Stage HER2 Low, Hormone Receptor Positive Breast Cancer | recruiting | Phase 2 | 88 | Jonsson Comprehensive Cancer CenterOTHER | 1 | Nov 10, 2025 |
| clinicaltrials |
| NCT06749210 | DAANCE FOR CHEMOTHERAPY-INDUCED NEUROPATHY(DAANCE) | recruiting | Phase 2 | 140 | Ohio State University Comprehensive Cancer CenterOTHER | 1 | Nov 5, 2025 | clinicaltrials |
| NCT05902988 | A Phase I/II Study of VLS-1488 in Subjects With Advanced Cancer | recruiting | Phase 1 / Phase 2 | 200 | Volastra Therapeutics, Inc.INDUSTRY | 1 | Nov 4, 2025 | clinicaltrials |
| NCT07016399 | Neoadjuvant Darolutamide Alone or in Combination With Standard Therapy for Stage II-IIIA, AR+, TNBC | recruiting | Phase 2 | 51 | Vandana AbramsonOTHER | 1 | Oct 30, 2025 | clinicaltrials |
| NCT06954831 | Ultra-hypofractionated Whole Breast Irradiation With Lumpectomy Cavity Boost for the Treatment of Stage I-III Breast Cancer | recruiting | Phase 2 | 82 | City of Hope Medical CenterOTHER | 1 | Oct 29, 2025 | clinicaltrials |
| NCT06361940 | Molecular Analyses to Predict Pathways of Endocrine Resistance Following Short Term Neoadjuvant Endocrine Treatment in Patients With Hormone Receptor-Positive HER2-negative Breast Cancer(MAPPER) | recruiting | Phase 2 | 100 | Medical College of WisconsinOTHER | 1 | Oct 14, 2025 | clinicaltrials |
| NCT06260033 | Stereotactic Body Radiation Therapy and FES PET/CT Imaging for the Treatment of Oligoprogressive Estrogen Receptor Positive Metastatic Breast Cancer | recruiting | Phase 2 | 18 | City of Hope Medical CenterOTHER | 1 | Oct 6, 2025 | clinicaltrials |
| NCT00722228 | Autologous and Allogeneic Whole Cell Cancer Vaccine for Metastatic Tumors | recruiting | Phase 1 / Phase 2 | 50 | Hadassah Medical OrganizationOTHER | 1 | Oct 2, 2025 | clinicaltrials |
| NCT05296564 | Anti-NY-ESO-1 TCR-Gene Engineered Lymphocytes Given by Infusion to Patients With NY-ESO-1 -Expressing Metastatic Cancers | recruiting | Phase 1 / Phase 2 | 3 | Hadassah Medical OrganizationOTHER | 1 | Oct 2, 2025 | clinicaltrials |
| NCT06178159 | DV in Combination With Pertuzumab With or Without Toripalimab Neoadjuvant Therapy With HER2-positive Breast Cancer | recruiting | Phase 2 | 40 | RemeGen Co., Ltd.INDUSTRY | 1 | Oct 1, 2025 | clinicaltrials |
| NCT06042894 | A Study of SI-B003 or BL-B01D1+SI-B003 in Patients With Unresectable Locally Advanced or Recurrent Metastatic HER2 Negative Breast Cancer | recruiting | Phase 2 | 58 | Sichuan Baili Pharmaceutical Co., Ltd.INDUSTRY | 1 | Sep 26, 2025 | clinicaltrials |
| NCT05866432 | Phase II Study of Dato-DXd in Triple-negative Breast Cancer Patients With Newly Diagnosed or Progressing Brain Metastases(TUXEDO-2) | recruiting | Phase 2 | 20 | Medical University of ViennaOTHER | 1 | Sep 25, 2025 | clinicaltrials |
| NCT06335069 | 18F-FDG Versus 68Ga-FAPI-46 as PET Tracer in ER-positive Breast Cancer. | recruiting | Phase 2 | 20 | Maastricht University Medical CenterOTHER | 1 | Sep 24, 2025 | clinicaltrials |
| NCT05381038 | Optimizing and Personalising Azacitidine Combination Therapy for Treating Solid Tumours QPOP and CURATE.AI | recruiting | Phase 1 / Phase 2 | 10 | National University Hospital, SingaporeOTHER | 1 | Sep 23, 2025 | clinicaltrials |
| NCT05795101 | TRUDI: TDXD+Durva in HER2+/Low IBC(TRUDI) | recruiting | Phase 2 | 63 | Filipa Lynce, MDOTHER | 1 | Sep 19, 2025 | clinicaltrials |
| NCT05329532 | Modi-1 Moditope in Breast, Head and Neck, Ovarian, or Renal Cancer(ModiFY) | recruiting | Phase 1 / Phase 2 | 168 | Scancell LtdINDUSTRY | 1 | Sep 17, 2025 | clinicaltrials |
| NCT07169994 | A Study of YL202 in Combination With Other Anti-tumor Therapies in Patients With Advanced Solid Tumors | recruiting | Phase 1 / Phase 2 | 414 | MediLink Therapeutics (Suzhou) Co., Ltd.INDUSTRY | 1 | Sep 12, 2025 | clinicaltrials |
| NCT04138719 | Nab-paclitaxel Plus Carboplatin Versus Nab-paclitaxel Plus Epirubicin in the Neoadjuvant Therapy for Breast Cancer | recruiting | Phase 2 | 520 | Hebei Medical University Fourth HospitalOTHER | 1 | Sep 11, 2025 | clinicaltrials |
| NCT04159142 | Nab-paclitaxel Plus Carboplatin Versus Nab-paclitaxel Plus Capecitabine in the Treatment of Advanced Triple-negative Breast Cancer | recruiting | Phase 2 | 414 | Hebei Medical University Fourth HospitalOTHER | 1 | Sep 11, 2025 | clinicaltrials |
| NCT06682793 | A Study to Evaluate the Safety and Efficacy of A2B395, an Allogeneic Logic-gated CAR T, in Participants With Solid Tumors That Express EGFR and Have Lost HLA-A*02 Expression(DENALI-1) | recruiting | Phase 1 / Phase 2 | 240 | A2 Biotherapeutics Inc.INDUSTRY | 1 | Sep 9, 2025 | clinicaltrials |
| NCT07162298 | Dragon Boat Race Versus Family Unsupervised Training to Improve the Physical Function and Quality of Life in Breast Cancer Patients | recruiting | Phase 2 | 72 | First Affiliated Hospital of Zhejiang UniversityOTHER | 1 | Sep 9, 2025 | clinicaltrials |
| NCT05900206 | Trastuzumab Deruxtecan Versus Standard Neoadjuvant Treatment for HER2-positive Breast Cancer(ARIADNE) | recruiting | Phase 2 | 370 | Karolinska University HospitalOTHER | 1 | Sep 2, 2025 | clinicaltrials |
| NCT07134153 | Phase I/II Study of Intrathecal/Ommaya T-DXd in HER2-Expressing Breast Cancer With Leptomeningeal/Brain Metastases(INOVATE) | recruiting | Phase 1 / Phase 2 | 139 | Fudan UniversityOTHER | 1 | Aug 21, 2025 | clinicaltrials |
| NCT03740893 | PHOENIX DDR/Anti-PD-L1 Trial: A Pre-surgical Window of Opportunity and Post-surgical Adjuvant Biomarker Study of DNA Damage Response Inhibition With or Without Anti-PD-L1 Immunotherapy in Patients With Neoadjuvant Treatment Resistant Residual Triple Negative Breast Cancer(PHOENIX) | recruiting | Phase 2 | 119 | Institute of Cancer Research, United KingdomOTHER | 1 | Aug 11, 2025 | clinicaltrials |
| NCT07113613 | Prospective Study on Exemption of Tumor Bed Boost Radiotherapy for pCR Patients After Breast Conserving Surgery With Neoadjuvant Therapy | recruiting | Phase 2 | 150 | The First Affiliated Hospital with Nanjing Medical UniversityOTHER | 1 | Aug 11, 2025 | clinicaltrials |
| NCT07108309 | BCD-236 in Combination With Chemotherapy in Patients With Relapsed and/or Metastatic Triple Negative Breast Cancer(AREAL) | recruiting | Phase 2 | 124 | BiocadINDUSTRY | 2 | Aug 7, 2025 | clinicaltrials |
| NCT07104266 | Triple Negative Breast Cancer and Celecoxib. Pilot Study | recruiting | Phase 2 | 30 | Université de SherbrookeOTHER | 1 | Aug 5, 2025 | clinicaltrials |
| NCT05035745 | Selinexor & Talazoparib in Advanced Refractory Solid Tumors; Advanced/Metastatic Triple Negative Breast Cancer (START) | recruiting | Phase 1 / Phase 2 | 63 | National University Hospital, SingaporeOTHER | 1 | Jul 25, 2025 | clinicaltrials |
| NCT05181033 | Lenvatinib+Letrozole Versus Fulvestrant in Metastatic ER+/HER2- Breast Cancer, Post Progression on Al + CDK4/6 Inhibitor | recruiting | Phase 2 | 120 | National University Hospital, SingaporeOTHER | 1 | Jul 25, 2025 | clinicaltrials |
| NCT05491083 | Pembrolizumab and ADG106 in Advanced Solid Cancers and Triple Negative Breast Cancer(ComPACT) | recruiting | Phase 1 / Phase 2 | 51 | National University Hospital, SingaporeOTHER | 1 | Jul 25, 2025 | clinicaltrials |
| NCT05086692 | A Beta-only IL-2 ImmunoTherapY Study(ABILITY-1) | recruiting | Phase 1 / Phase 2 | 115 | Medicenna Therapeutics, Inc.INDUSTRY | 7 | Jul 9, 2025 | clinicaltrials |
| NCT06402435 | SBRT, Chemotherapy, and AK112 Neoadjuvant Therapy for Luminal-type Breast Cancer | recruiting | Phase 2 | 50 | Hubei Cancer HospitalOTHER | 1 | Jul 2, 2025 | clinicaltrials |
| NCT06500208 | Neoadjuvant Adebrelimab and Chemotherapy in High-rish ER+/HER2- BC | recruiting | Phase 2 | 48 | Shanghai Jiao Tong University School of MedicineOTHER | 1 | Jun 26, 2025 | clinicaltrials |
| NCT06665178 | Genomic and Transcriptomic Predictors of Sequential SG Sensitivity After T-DXd in ER+/HER2-Low Metastatic Breast Cancer | recruiting | Phase 2 | 20 | British Columbia Cancer AgencyOTHER | 1 | Jun 25, 2025 | clinicaltrials |
| NCT06568692 | A Phase 2 Study of PCS6422 With Capecitabine in Patients With Advanced or Metastatic Breast Cancer | recruiting | Phase 2 | 90 | Processa PharmaceuticalsINDUSTRY | 1 | Jun 19, 2025 | clinicaltrials |
| NCT06150898 | Ketorolac and Pregabalin Effects on breaSt Cancer (KePreSt)(KePreSt) | recruiting | Phase 2 | 112 | Jules Bordet InstituteOTHER | 1 | Jun 13, 2025 | clinicaltrials |
| NCT07014410 | Pyrotinib Combined With Dalpiciclib Combined With Letrozole in ER-positive and HER2-positive Advanced Breast Cancer | recruiting | Phase 2 | 63 | Zhejiang Cancer HospitalOTHER | 1 | Jun 11, 2025 | clinicaltrials |
| NCT06678048 | Arsenous Acid for Refractory Triple-Negative Breast Cancer | recruiting | Phase 2 | 12 | Sun Yat-sen UniversityOTHER | 1 | Jun 6, 2025 | clinicaltrials |
| NCT06993714 | 3D-printed Biodegradable Breast Implants for Breast Restoration | recruiting | Phase 2 | 120 | Xijing HospitalOTHER | 1 | Jun 6, 2025 | clinicaltrials |
| NCT06677879 | A Prospective Cohort Study of Proton and Photon Therapy for Left-sided Breast Cancer. | recruiting | Phase 2 | 780 | Shanghai Proton and Heavy Ion CenterOTHER | 1 | May 30, 2025 | clinicaltrials |
| NCT06049355 | EMBRACE: Exercising Together | recruiting | Phase 2 | 400 | OHSU Knight Cancer InstituteOTHER | 1 | May 29, 2025 | clinicaltrials |
| NCT06992336 | Circulating Tumor DNA Guided Boost Therapy in Early Triple Negative Breast Patients With Residual Disease After Neoadjuvant Therapy | recruiting | Phase 2 | 411 | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen UniversityOTHER | 1 | May 28, 2025 | clinicaltrials |
| NCT06367088 | Cadonilimab Combined With Chemotherapy as First or Second Line Treatment in Recurrent or Metastatic Triple Negative Breast Cancer | recruiting | Phase 2 | 27 | Union Hospital, Tongji Medical College, Huazhong University of Science and TechnologyOTHER | 1 | May 20, 2025 | clinicaltrials |
| NCT04947189 | Seviteronel in Combination With Chemotherapy in Androgen-receptor Positive Metastatic Triple-negative Breast Cancer(4CAST) | recruiting | Phase 1 / Phase 2 | 65 | St Vincent's Hospital, SydneyOTHER | 1 | May 15, 2025 | clinicaltrials |
| NCT06165419 | Definitive Radiation for High-Risk Spine Metastases | recruiting | Phase 2 | 26 | Stony Brook UniversityOTHER | 1 | May 14, 2025 | clinicaltrials |
| NCT06958627 | The Impact of Intelligent Patient Management Model on Medication Adherence of Pyrotinib Compared to Traditional Patient Management Model: a Prospective, Multicenter, Randomized Controlled Clinical Study(any) | recruiting | Phase 2 / Phase 3 | 964 | Cancer Institute and Hospital, Chinese Academy of Medical SciencesOTHER | 1 | May 6, 2025 | clinicaltrials |
| NCT04503265 | A Trial of AMXI-5001 for Treatment in Patients With Advanced Malignancies | recruiting | Phase 1 / Phase 2 | 122 | AtlasMedx, IncorporatedINDUSTRY | 1 | May 1, 2025 | clinicaltrials |
| NCT06207734 | Discontinuation of CDK4/6 Inhibitors in Patients With Metastatic HR Positive, HER2 Negative Breast Cancer | recruiting | Phase 2 | 120 | Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus NordwestOTHER | 1 | May 1, 2025 | clinicaltrials |
Data updated 23 days agoSource updated Nov 14, 2025source: clinicaltrials